Ascletis will report the latest preclinical research results of two new anti-cancer drugs, ASC61 and ASC60, at this year's annual meeting of the American Association for Cancer Research

Ascletis Pharma Co.
, Ltd.
(SEHK: 1672) recently announced the latest preclinical research results of the company's 2 new anti-cancer drugs, the oral PD-L1 small molecule inhibitor ASC61 and the fatty acid synthase (FASN) inhibitor ASC60 Inducted for the 2022 American Association for Cancer Research (AACR) Annual Meeting ("2022 AACR Annual Meeting")
.
The abstract content is now available on the AACR website
.
The AACR Annual Meeting is one of the oldest and largest academic conferences on oncology research in the world
.
The conference focuses on all aspects of high-quality oncology research and innovation.
It is the focus of global oncology research and brings together the most cutting-edge research results in the field of oncology
.
The AACR Annual Meeting will be held in New Orleans, Louisiana, USA from April 8 to 13, 2022 Central Time
.
The abstract information of the poster presentations selected for the 2022 AACR annual meeting is as follows: (1) ASC61 Abstract title: In vivo efficacy evaluation of the oral PD-L1 inhibitor ASC61 in two tumor mouse models Report format: Poster presentation abstract number: 5529 Conference Category: Immunization Conference Theme: Preclinical Research on Immunotherapy Time: April 8, 2022, 12:00-1:00 pm CST Speaker/Author: Wu Jinzi, He Hanli, Ascletis Biotechnology (Hangzhou) Co.
, Ltd.
The company's ASC61 is a potent and highly selective oral PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing the formation and endocytosis of PD-L1 dimers
.
Preclinical studies have shown that in both syngeneic tumor mouse models and humanized tumor mouse models, ASC61 significantly inhibits tumor growth, and its tumor inhibitory effect is better than or comparable to that of atezolizumab (atezolizumab, which has been obtained).
FDA-approved PD-L1 therapeutic monoclonal antibodies) are comparable and well tolerated
.
The U.
S.
Phase I clinical trial application for ASC61 in patients with advanced solid tumors has been approved by the FDA, and the first patient is expected to be enrolled in the second quarter of 2022
.
(2) ASC60 Abstract title: Validation of the efficacy of oral fatty acid synthase inhibitor ASC60 in two tumor mouse models Report format: Poster presentation Abstract number: 5466 Conference category: Experimental and molecular therapy Conference topic: Small molecule therapeutic drugs Report time : April 8, 2022, 12:00-1:00 pm CST Reporters/authors: Wu Jinzi, He Hanli, Ascletis Biotechnology (Hangzhou) Co.
, Ltd.
ASC60 is a potent, selective and safe Oral small-molecule fatty acid synthase (FASN) inhibitors disrupt metabolism and tumor-associated signaling in tumor cells by blocking de novo fatty acid synthesis (DNL)
.
Preclinical mouse tumor model studies have shown that ASC60 can effectively inhibit tumor growth and enhance the tumor suppressive effect of mPD-1 antibody
.
Ascletis has submitted an application for a Phase I clinical trial of ASC60 in the treatment of advanced solid tumors to the Center for Drug Evaluation of the State Drug Administration of China
.
"We are delighted that the preclinical studies of ASC61 and ASC60 have been selected for the 2022 AACR Annual Meeting
," said Dr.
Jinzi Wu, founder, chairman and CEO of Ascletis.
"The oral PD-L1 inhibitor ASC61 and oral fatty acid synthase (FASN) inhibition Agent ASC60 has better patient compliance and is easier to use in combination with other oral antitumor drugs
.
These preclinical animal studies help us better understand the mechanism of action of our drug candidate and antitumor activity in animal models, and advance Clinical Development of Ascletis Oncology Pipeline
.
A phase III clinical trial of fatty acid synthase (FASN) inhibitor ASC40 in combination with bevacizumab in recurrent glioblastoma (rGBM) is currently underway, and we are also exploring ASC61 and ASC40 (or ASC60) and The possibility of combining oral antineoplastic drugs from our business partners to form an all-oral regimen
.
"